Clinical assessment of human gonadotrophins produced by recombinant DNA technology.
Loumaye
E
E
Corporate Medical Affairs Department, Ares-Serono, Geneva, Switzerland.
Martineau
I
I
Piazzi
A
A
O'Dea
L
L
Ince
S
S
Howles
C
C
Decosterd
G
G
Van Loon
K
K
Galazka
A
A
D000818:Animals; D016466:CHO Cells; D006063:Chorionic Gonadotropin / Q000096:biosynthesis / Q000235:genetics* / Q000627:therapeutic use; D006224:Cricetinae; D004353:Drug Evaluation, Preclinical; D005260:Female; D005640:Follicle Stimulating Hormone / Q000096:biosynthesis / Q000235:genetics* / Q000627:therapeutic use; D005818:Genetic Engineering; D006801:Humans; D007986:Luteinizing Hormone / Q000096:biosynthesis / Q000235:genetics* / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000627:therapeutic use
D006063:Chorionic Gonadotropin; D011994:Recombinant Proteins; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone